Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Commentary
  • Published:

Vaccines in the public eye

Nature Medicine volume 11, pages S20–S24 (2005)Cite this article

Preventive vaccines are widely acknowledged as the best hope for protection against infectious pathogens such as avian flu, HIV and SARS. As a result, they have received much recent attention in the media that has exposed some of the challenges involved in optimally using vaccine technology.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Diamond, J. Guns, Germs and Steel (W.W. Norton & Company, New York, 1999).

    Google Scholar 

  2. Potter, C.W. in Textbook of Influenza (eds Nicholson, K.G., Webster, R.G. & Hay, A.J.) 3–18 (Blackwell Science, Oxford, 1998).

    Google Scholar 

  3. Donnelly, C.A. et al. Lancet Infect. Dis. 4, 672–683 (2004).

    Article  CAS  Google Scholar 

  4. World Health Organization. Summary table of SARS cases by country, 1 November 2002 – 7 August 2003 <http://www.who.int/csr/sars/country/en/country2003_08_15.pdf> (2003).

  5. Knobler, S.L., Mack, A., Mahmoud, A. & Lemon, S.M. (eds). The threat of pandemic influenza: are we ready? Workshop summary report by the Board on Global Health, Institute of Medicine. (National Academies Press, Washington, DC, 2004).

    Google Scholar 

  6. Weiss, R.A. & McMichael, A.J. Nat. Med. 10, S70–S76 (2004).

    Article  CAS  Google Scholar 

  7. Kremer, M. in Global Public Goods Financing: New Tools for New Challenges, A Policy Dialogue (eds Kaul, I., Goulven, K. & Schnupf, M.) 37–42 (UNDP/ODS, New York, 2002).

    Google Scholar 

  8. Kremer, M. & Glennerster, R. A World Bank vaccine commitment. Brookings Institution Policy Brief #57 <http://www.brookings.edu/comm/policybriefs/pb57.htm> (2000).

  9. Plotkin, S.L. & Plotkin, S.A. in Vaccines (eds Plotkin, S.A. & Orenstein W.A.) 1–11 (Saunders, Philadelphia, 1999).

    Google Scholar 

  10. Slovic, P. Science 236, 280 (1987)

    Article  CAS  Google Scholar 

  11. Greenberg, S. South. Med. J. 93, 763–767 (2000).

    CAS  PubMed  Google Scholar 

  12. Hennock, E.P. Soc. Hist. Med. 11, 49–71 (1998).

    Article  CAS  Google Scholar 

  13. Gellin, B.G., Maibach, E.W. & Marcuse, E.K. Pediatrics 106, 1097–1102 (2000).

    Article  CAS  Google Scholar 

  14. Mieczkowski, T.A. & Wilson, S.A. Vaccine 18, 1383–1392 (2002).

    Article  Google Scholar 

  15. Liau, A. & Zimet, G.D. AIDS Care 13, 643–650 (2001)

    Article  CAS  Google Scholar 

  16. Liau, A. & Zimet, G.D. Int. J. STD AIDS 11, 445–450 (2000)

    Article  CAS  Google Scholar 

  17. Zimet, G.D., Blythe, M.J. & Fortenberry, J.D. Int. J. STD AIDS 11, 143–149 (2000).

    Article  CAS  Google Scholar 

  18. Honkanen, P.O., Keistinen, T. & Kivela, S.L. Public Health 110, 163–168 (1996).

    Article  CAS  Google Scholar 

  19. Zimet, G.D., Fortenberry, J.D. & Blythe, M.J. J. Pediatr. Psychol. 24, 67–75 (1999).

    Article  Google Scholar 

  20. Webb, P.M., Zimet, G.D., Mays, R. & Fortenberry, J.D. J. Adoles. Health 25, 320–322 (1999).

    Article  CAS  Google Scholar 

  21. Liau, A, Zimet, G.D. & Fortenberry, J.D. Sex. Transm. Dis. 25, 76–81 (1998).

    Article  Google Scholar 

  22. Nichol, K.L. & Zimmerman, R. Arch. Intern. Med. 161, 2702–2708 (2001).

    Article  CAS  Google Scholar 

  23. Nichol, K.L., Lofgren, R.P. & Gapinski, J. Arch. Intern. Med. 152, 106–10 (1992).

    Article  CAS  Google Scholar 

  24. McPhillips, H.A., Davis, R.L., Marcuse, E.K. & Taylor, J.A. Arch. Pediatr. Adolesc. Med. 155:1051–1056 (2001).

    Article  CAS  Google Scholar 

  25. Fiebach, N.H. & Viscoli, C.M. Am. J. Med. 91, 393–400 (1991).

    Article  CAS  Google Scholar 

  26. Mezaros J.R. et al. J. Clin. Epidemiol. 49, 697–703 (1996).

    Article  Google Scholar 

  27. Ritvo, P. et al. J. Immune Based Ther. Vaccines 1, 3 (2003).

    Article  Google Scholar 

  28. Abraham, J. Lancet 360, 1498–1502 (2002).

    Article  Google Scholar 

  29. Keller-Stanislawski, B. Vaccine 20, S45–S46 (2002).

    Article  Google Scholar 

  30. Hernan, M.A., Jick, S.S., Olek, M.J. & Jick, H. Neurology 63, 838–842 (2004).

    Article  Google Scholar 

  31. Immunization Safety Committee. Immunization safety review: hepatitis B vaccine and demyelinating neurological disorders (National Academy Press, Washington, DC, 2002).

  32. DeStefano, F. et al. Arch. Neurol. 60, 504–509 (2003).

    Article  Google Scholar 

  33. Ascherio, A. et al. N. Engl. J. Med. 344, 327–332 (2001).

    Article  CAS  Google Scholar 

  34. Confavreux, C., Suissa, S., Saddier, P., Bourdes, B. & Vukusic, S. N. Engl. J. Med. 344, 319–326 (2001).

    Article  CAS  Google Scholar 

  35. Sadovnick, A.D. & Scheifele, D.W. Lancet 355, 549–550 (2000).

    Article  CAS  Google Scholar 

  36. World Health Organization Global Advisory Committee on Vaccine Safety. Response to the paper by MA Hernán and others in Neurology 14th September 2004 issue entitled “Recombinant Hepatitis B Vaccine and the Risk of Multiple Sclerosis” <http://www.who.int/vaccine_safety/topics/hepatitisb/multiple_sclerosis/sep_04/en/> (2004).

  37. Levy-Bruhl, D., Desenclos, J.C., Rebiere, I. & Drucker, J. Vaccine 20, 2065–2071 (2002).

    Article  Google Scholar 

  38. Touzé, E., Gout, O., Verdier-Taillefer, M.H., Lyon-Caen, O. & Alpérovitch, A. Rev. Neurol. 152, 242–246 (2000).

    Google Scholar 

  39. Touzé, E., Fourrier, A., Rue-Fenouche, C., Rondé-Ousteau, V., Jeantaud, I. & Bé gaud, B. Neuroepidemiology 21, 180–186 (2002).

    Article  Google Scholar 

  40. Sturkenboom, M.C.J.M. et al. Pharmacoepidemiol. Drug Saf. 8, S170–S171 (1999).

    Google Scholar 

  41. Cage, S. WHO: Islamic state in Nigeria will resume polio vaccinations in early July. Associated Press 30 June 2004.

  42. Qadir, A. India gears up for last mile of polio eradication but poor shun vaccine drops in eastern state. Associated Press 28 August 2004.

  43. Renn, O. Risk communication and social amplification of risk. In Communicating Risks to the Public: International Perspectives (eds. Kasperson, RE. & Stallen, P.M.) (Kluwer, Amsterdam, 1991).

    Google Scholar 

  44. Powell, D. & Leiss, W. Mad Cows and Mother's Milk: The Peril of Poor Risk Communication (McGill-Queen's University Press, Montreal, 1997).

    Google Scholar 

  45. UK Department of Health. Statistical Bulletin: NHS Immunization Statistics 2003-04 (UK Department of Health, London, 2004).

  46. Wakefield, A.J. et al. Lancet 351, 637–641 (1998).

    Article  CAS  Google Scholar 

  47. Murch, S.H., et al. Lancet 363(9411), 750 (2004).

    Article  Google Scholar 

  48. Ward, L. Minister outlines steps to boost image of MMR jabs. The Guardian. 21 February 2002.

    Google Scholar 

  49. Jansen, V.A. et al. Science 301, 804 (2003).

    Article  CAS  Google Scholar 

  50. Krahn, M. et al. Vaccine 23, 1549–1558 (2005).

    Article  Google Scholar 

  51. Kremer, A. A Purchase Commitment for Vaccines. in Global Public Goods Financing: New Tools for New Challenges, A Policy Dialogue. (ed. Kaul, I., le Goulven, K. & Schnupf, M.) 37–42 (UNDP/ODS, New York, 2002).

    Google Scholar 

  52. Muraskin, W., Hotez, P. & Sachs, J. Vaccines for developing economies – who will pay? The Albert Sabin Vaccine Institute Colloquium at Cold Spring Harbor (The Albert B. Sabin Vaccine Institute, New Canaan, Connecticut, 2001).

    Google Scholar 

  53. Horton, R. Lancet 364, 2071–2074 (2004).

    Article  Google Scholar 

  54. Hirschler, B. Chirac calls for global tax to fight AIDS. The Toronto Star. January 27, 2005.

    Google Scholar 

  55. Ungchusak, K. et al. N. Eng. J. Med. 352, 333–3640 (2005).

    Article  CAS  Google Scholar 

  56. Alonso, P.L. et al. Lancet 364, 1411–1420 (2004).

    Article  CAS  Google Scholar 

  57. Harper, D.M. et al. Lancet 364, 1757–1765 (2004).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors want to acknowledge expert assistance from D. Levy-Bruhl (Départment des Maladies Infectieuses Institut de Veille Sanitaire) in the preparation of this manuscript, and M. Kremer (Department of Economics, Harvard University and the Brookings Institution) for helpful review and comments.

Author information

Authors and Affiliations

  1. School of Kinesiology and Health Sciences and Department of Psychology, York University, Toronto, M3J 1P3, Ontario, Canada

    Paul Ritvo

  2. Departments of Medicine and Health Policy Management and Evaluation, University of Toronto, Toronto General Hospital, Toronto, M5G 2C4, Ontario, Canada

    Paul Ritvo, Kumanan Wilson & Ross Upshur

  3. Department of Anthropology, McMaster University, Hamilton, L8S 4L9, Ontario, Canada

    Dennis Willms

  4. Sunnybrook Women's Health Science Centre, Primary Care Research Unit, Toronto, M4N 3M5, Ontario, Canada

    Ross Upshur

  5. School of Kinesiology and Health Sciences, York University, Toronto, M3J 1P3, Ontario, Canada

    Adam Goldman

  6. Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network, Toronto, M5G 2C4, Ontario, Canada

    David Kelvin

  7. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, L8N 3Z5, Ontario, Canada

    Kenneth L Rosenthal

  8. Canadian Network for Vaccines and Immunotherapeutics, Montreal, H3A 3C6, Quebec, Canada

    Aline Rinfret

  9. Department of Medicine, University of Toronto, Toronto, M5F 1A8, Ontario, Canada

    Rupert Kaul

  10. Departments of Medicine, Pharmacy and Health Policy Management and Evaluation, University of Toronto, Toronto General Hospital, Toronto, M5G 2C4, Ontario, Canada

    Murray Krahn

Authors
  1. Paul Ritvo
    View author publications

    Search author on:PubMed Google Scholar

  2. Kumanan Wilson
    View author publications

    Search author on:PubMed Google Scholar

  3. Dennis Willms
    View author publications

    Search author on:PubMed Google Scholar

  4. Ross Upshur
    View author publications

    Search author on:PubMed Google Scholar

Consortia

for the CANVAC Sociobehavioural Study Group

  • Adam Goldman
  • , David Kelvin
  • , Kenneth L Rosenthal
  • , Aline Rinfret
  • , Rupert Kaul
  •  & Murray Krahn

Corresponding author

Correspondence to Paul Ritvo.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ritvo, P., Wilson, K., Willms, D. et al. Vaccines in the public eye. Nat Med 11 (Suppl 4), S20–S24 (2005). https://doi.org/10.1038/nm1220

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nm1220

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing